Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mapping the dialogue: Decoding alveolar stem-niche interactions.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Breaking the cycle: should we target inflammation, fibrosis, or both?

Frontiers in immunology·2025
Same author

Transcriptional fingerprinting of regulatory T cells: ensuring quality in cell therapy applications.

Frontiers in immunology·2025
Same author

YAP/TAZ activity in PDGFRα-expressing alveolar fibroblasts modulates AT2 proliferation through Wnt4.

Cell reports·2025
Same author

Dual inhibition of TGFβ2,3 is severely toxic, whereas selective inhibition of TGFβ1, 2, or 3 and dual inhibition of TGFβ1,2 is generally tolerated in mouse and cynomolgus monkey toxicology studies.

Toxicological sciences : an official journal of the Society of Toxicology·2025
Same author

Interference with systemic negative feedback as a potential mechanism for nonmonotonic dose-responses of endocrine-disrupting chemicals.

Toxicological sciences : an official journal of the Society of Toxicology·2025

Related Experiment Video

Updated: May 13, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Redefining approaches to asthma: developing targeted biologic therapies.

Joseph R Arron1, Heleen Scheerens, John G Matthews

  • 1Genentech, Inc., South San Francisco, CA, USA. arron.joseph@gene.com

Advances in Pharmacology (San Diego, Calif.)
|February 26, 2013
PubMed
Summary

Biologic therapies targeting type 2 airway inflammation show promise for severe asthma. Drug development focuses on target, molecule, outcome, and patient selection, with biomarkers playing a key role.

More Related Videos

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

Related Experiment Videos

Last Updated: May 13, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Asthma is a chronic respiratory disease often linked to type 2 airway inflammation.
  • Many patients have uncontrolled symptoms despite standard treatments, representing a significant unmet need.
  • Biologic therapies targeting type 2 inflammation mediators are under development.

Purpose of the Study:

  • To review the biological functions of therapeutic targets in asthma.
  • To analyze clinical trial data for biologic agents targeting asthma.
  • To discuss drug development components and the role of biomarkers.

Main Methods:

  • Review of biological functions of asthma therapeutic targets.
  • Analysis of clinical trial data for biologic asthma therapies.
  • Discussion of drug development strategies: target, molecule, outcome, and patient selection.

Main Results:

  • Biologic therapies targeting type 2 inflammation are a focus for severe, refractory asthma.
  • Clinical trial outcomes are being evaluated based on drug development components.
  • Biomarkers are increasingly important in selecting patients and guiding development.

Conclusions:

  • Biologic therapies offer a new avenue for managing severe asthma.
  • Optimizing drug development through careful selection processes is crucial.
  • Biomarker utilization enhances the precision of asthma treatment development.